In recent years, SEO (search engine optimization) services have gained popularity and many SEO companies or agencies have cropped up to offer SEO services in Malaysia.
There are also outright scams from "bad apples" in the industry that had led you to be disappointed. The popularity of Google search engine optimization (SEO) and number one ranking is one of the primary selling features.
You should learn more about Google SEO from Google. Get direct updates and credible information directly from Google itself. Free resources such as Google Search Console, the official Webmaster Central blog, and Google’s discussion forum can provide you with a great deal of information about how to optimize your site for organic search.
Best SEO Companies in Selangor
The selection of the SEO companies below is based on Google Search Results and information available on blogs and forums. The top SEO companies in Malaysia have been arranged in no particular order. Here is the list.
1. Locus - T Online Sdn Bhd
Website : https://www.locus-t.com.my/
Facebook : https://www.facebook.com/locustMY/
Whatsapp : +6017-300 2078
Address: 72, Jalan 17/22, Seksyen 17, 47400 Petaling Jaya, Selangor
LOCUS-T is an Internet Marketing Agency, a company that is packed with 18 years of Internet Marketing experience.
Highlights
- Eligible for BSN SME Grant, up to 50% or up to RM5000 waiver
- Google SEO (Search Engine Optimization), Google Ads, Facebook Ads and Website Design
- Served over 7000 MNCs and SMEs
- Over 20 years experience in web development and web design
Testimonials
Locus-T helped position my company well on Google, and brought in 700% ROI during the first month.Besides the great results, their team is responsive and attentive to changes needed month by month. I would recommend them if you want your company to have a competitive online presence.
Address : C-20-05, Level 20, Colonial Loft, Empire City, Jalan PJU 8/1, Damansara Perdana, 47820, Petaling Jaya, Selangor
What sets this company apart is the clarity and comprehensiveness of the entire process. You can expect little to no failures in their strategies, which will be based around the structure and missions of your business. Their service will be tailor fit and extensive, providing both on-site optimisation as well as copywriting to help you get ahead of your competition.
Services : SEO, Google Ads, Facebook Ads, Website Development, Video Production, Copywriting
Testimonial
Kempen Facebook Ads kami dapat return yang lebih tinggi bila Bomstart Media yang handle. Masa buat sendiri kami hanya boleh dapat ROAS sekitar 5 sahaja. Bila Bomstart buat, dapat ROAS sehingga 20. Bomstart Media terbaik.. 👍👍👍
Address: A-06-07, Prima Avenue, Jalan PJU 1/39, Dataran Prima, 47301 Petaling Jaya, Selangor
"You’re reading this because you found us on Google. We compete with some of the top SEO service providers in the country and yet we still outranked them. Besides, if you are not ranked on Google, your competitors will be and they will the be the ones that reach out to your customers. SEO is no longer a nice to have, it is a must have for any business or company. Imagine waking up with customers contacting you for your products or services, all day, everyday. We know how that feels like and it is amazing."
Highlights
- Google Rankings or the bears will work for free : Free if you don't show up on page 1 of Google within 90 days
- Over 700 projects completed
Testimonial
I chanced upon Bike Bear when I was Google searching for a website design company. Being a marketer, I was very meticulous about the quality of work. I didn't want mere designers to do the job, no matter how great their aesthetic sense may be... I wanted people who understood how their design and website development can help propel my business goals.
1 and a half years later, I'm glad to say I have found a reliable and strong partner. Their design is not only great, they also took the effort to support our business goals through strategic website development and marketing campaigns.
Till this day, I still find it amusing that I found them through a Google Search. Needless to say, their SEO team must have done something right.
Really grateful to have Ariel, Jason and their excellent team seeing us through numerous websites and marketing campaigns. Hey, they even won us an award through our official website.
Top gold ETFs to watch in 2025 span U.S., Indian, Europe and Chinese markets, offering both physical gold exposure and mining stock leverage. Based on the latest performance, expense ratios, and trends, key ETFs include: SPDR Gold MiniShares Trust (GLDM) : The best-performing gold ETF by one-year return in 2025, up around 44%, with a very low expense ratio (0.10%). It tracks physical gold closely and is highly liquid, making it a top choice for cost-conscious investors seeking strong recent gains ( 2 , 1 ). iShares Gold Trust Micro (IAUM) : Nearly matching GLDM’s performance with a 43.86% one-year gain and an even lower expense ratio (0.09%), this is an excellent low-cost option for gold exposure ( 2 ). abrdn Physical Gold Shares ETF (SGOL) : With about a 43.8% one-year return and expense ratio around 0.17%, this fund holds physical gold bullion and appeals to investors seeking stable, direct gold exposure ( 2 , 1 ). GraniteShares Gold Trust (BAR) : Tracks physica...
Gold and silver ETFs are outperforming the S&P 500 index. But do these precious metals deserve a place in your investment portfolio? We provide a list of the best precious metals ETFs by 2025 performance, as well as the benefits and risks that investors need to know before buying these funds. The best gold and silver ETFs of 2025 stand out due to exceptional performance, low expense ratios, and reliable tracking of precious metals’ prices. Here are the top options across global and key regional markets as of July 2025: Best Gold ETFs of 2025 SPDR Gold MiniShares Trust (GLDM) 1-Year Return: 43.90% Expense Ratio: 0.10% Notes: Best performing gold ETF, tracks physical gold, high liquidity, and cost-effective for retail investors ( 1 , 2 ). iShares Gold Trust Micro (IAUM) 1-Year Return: 43.86% Expense Ratio: 0.09% Notes: Nearly matches GLDM in returns, with the lowest expense ratio among major gold ETFs ( 1 ). abrdn Physical Gold Shares ETF (S...
Executive Summary Algorithmic trading and investment analysis leverage advanced computer algorithms to automate and optimize trading decisions and portfolio management. Employing AI, machine learning, and real-time data, these systems enable faster, more accurate, and adaptive trading strategies that outperform traditional manual approaches. By 2025, algorithmic trading dominates global financial markets, with sophisticated AI models handling nearly 90% of trading volume (2), delivering significant competitive advantages, operational efficiency, and risk mitigation. This article discusses key trends and major related technologies shaping the current and near-future landscape of algorithmic trading and investment analysis. Introduction AI is fundamentally transforming algorithmic trading and investment analysis. By 2025, the fusion of advanced AI models, machine learning, and cloud platforms is making trading faster, more adaptive, and deeply data-driven for both institutional and retai...
As the cryptocurrency market matures in 2025, XRP ETFs have emerged as essential instruments for investors seeking regulated and accessible exposure to this dynamic digital asset. With a growing variety of futures-based and physically backed spot ETFs now available across major markets like the U.S., Canada, and Europe, understanding the nuances of these products—including their fee structures, holdings, and performance—is crucial for making informed investment decisions. This article highlights the top XRP ETFs to watch in 2025, providing deep insights into their dominating holdings, low fees, and recent market impact, all organized in a clear list format for easy navigation. Whether you are a long-term investor or an active trader, this guide will help you identify opportunities and risks in the evolving XRP ETF landscape. 1. Leading XRP ETFs in 2025 ProShares Ultra XRP ETF (UXRP) Type: 2x leveraged futures-based ETF listed in the U.S. Launched: July 18, 2025 Key Features...
Predicting what will happen in the markets is difficult, so we decided to see what AI had to say. We asked Grok 3 what July 2025 has in store for stocks, bitcoin, and more. Many try but few succeed in correctly predicting the markets — even among Wall Street analysts who do it for a living. Take the S&P 500, for example. The index closed 2024 at 5,882, cementing a second year of more than 20% gains. Yet at this time last year, Wall Street's 2024 median year-end price target was just 4,850, according to Bloomberg data. Not exactly close. Since experts are so often wrong, we figured it wouldn't be a bad idea to put Big Tech's trillion-dollar baby to work and ask AI for its predictions on the economy and markets going into 2025. Will Bitcoin or Nvidia go to the moon? Peak price prediction? We'll find out in next month... The S&P 500 will end the July 2025 month at 6,400. Grok 3 said: My specific forecast, leaning toward a cautious but optimistic scenario, is 6,400...
Here are the top 10 pharmaceutical companies by market cap as of July 2025. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 , 2 , 3 ). In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Credit: CompaniesMarketCap.com Lilly—boosted by...
Here are the top 10 pharmaceutical companies by revenue as of 2025, primarily based on first quarter 2025 revenue data. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 , 2 , 3 ). In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). While earnings and revenue reports are considered lagging indicators that reflect past performance, the following articles offer a more forward-looking perspective, highlighting the potential future performance of related...
Biopharma may soon be in for a blockbuster boom. In the latest edition of its annual ranking of the biggest potential drug launches of the coming year, Evaluate listed 10 drugs that are slated to earn approvals in 2025. According to the analysts’ forecasts, all together, the meds stand to generate a whopping $29 billion in annual sales by the end of the decade. That’s nearly double the estimate for last year’s top 10 . In that case, Evaluate calculated a conservative $15.2 billion in 2028 sales for 2024’s biggest expected launches, which included the likes of Bristol Myers Squibb’s schizophrenia drug Cobenfy , Eli Lilly’s Alzheimer’s disease med Kisunla and Madrigal Pharmaceuticals’ MASH treatment Rezdiffra in the top three—all of which were indeed approved throughout last year. In fact, 2025’s total is the highest in the last five years, topping even Evaluate’s high-flying forecast for 2022, when the analysts estimated total 2026 sales of $26.9 billion for the year’s most anticipat...
Sam Altman, the CEO of OpenAI, has prophesied that this may be the year the first "agents" — a set of artificial intelligence tools that can perform tasks on their own — "join the workforce." Investors whose job it is to back new technologies before they become ubiquitous are swooning at the promise of these digital coworkers. The rise of agents offers fertile ground for a select group of startups to establish themselves as the front-runners of this shift. In that spirit, Business Insider reviewed press releases, news articles, and PitchBook data for startups exploring the application of agents across various sectors and then filtered for those companies that raised rounds of more than $25 million and less than $75 million in 2024. The result is a list of 20 startups that seem positioned to scale this year on the back of new funding. "If 2024 was the year of LLMs, we believe 2025 will be the year of agentic AI," said Praveen Akkiraju, a man...
It’s been more than 12 years since the passing of Steve Jobs. Legendary Apple Inc., Co-founder Steve Jobs passed away at only 56 years old after battling pancreatic neuroendocrine tumor, a rare form of pancreatic cancer. A growing list of people in the public spotlight have faced pancreatic cancer, including tech innovators, entrepreneurs and influencers. In addition, and connected to Jobs, Jef Raskin, developer of the Macintosh computer, passed away of pancreatic cancer in 2005. And, coincidentally, Dag Kittlaus, creator of Siri, which was acquired by Apple in 2010, was diagnosed with the same exact cancer that took the life of Jobs. Pancreatic neuroendocrine tumors (or PNETs) account for less than 10% of all pancreatic cancer tumors and tend to grow slower than exocrine tumors, the most common type of pancreas tumors. Jobs survived eight years before dying of the disease on Oct. 5, 2011. The five-year survival rate for pancreatic cancer is only 10%. Since PNETs are so uncommon, trea...
Comments